Skip to main content
PMC home page
The AAPS Journal logoLink to The AAPS Journal
. 2005 Oct 5;7(2):E363–E373. doi: 10.1208/aapsj070237

Recommended reading in population pharmacokinetic pharmacodynamics

Peter L Bonate 1,✉
PMCID: PMC2750974  PMID: 16353916

Abstract

Developing the skills or expertise to create useful population pharmacokinetic-pharmacodynamic models can be a daunting task-the level of mathematical and statistical complexity is such that newcomers to the field are frequently overwhelmed. A good place to start in learning the field is to read articles in the literature. However, the number of articles dealing with population pharmacokinetic pharmacodynamics is exponentially increasing on a yearly basis, so choosing which articles to read can be difficult. The purpose of this review is to provide a recommended reading list for newcomers to the field. The list was chosen based on perceived impact of the article in the field, the quality of the article, or to highlight some important detail contained within the article. After reading the articles in the list, it is believed that the reader will have a broad overview of the field and have a sound foundation for moredetailed reading of the literature.

Keywords: NONMEM, influential articles, review, first-order approximation

Full Text

The Full Text of this article is available as a PDF (163.8 KB).

References

  • 1.Sheiner LB, Rosenberg B, Marathe V. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm. 1977;5:445–479. doi: 10.1007/BF01061728. [DOI] [PubMed] [Google Scholar]
  • 2.Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm. 1981;9:635–651. doi: 10.1007/BF01061030. [DOI] [PubMed] [Google Scholar]
  • 3.Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine pharmacokinetic data. J Pharmacokinet Biopharm. 1982;11:303–319. doi: 10.1007/BF01061870. [DOI] [PubMed] [Google Scholar]
  • 4.Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1980;8:553–571. doi: 10.1007/BF01060053. [DOI] [PubMed] [Google Scholar]
  • 5.Peck CC, Beal SL, Sheiner LB, Nichols AI. Extended least squares nonlinear regression: a possible solution to the “choice of weights” problem in analysis of individual pharmacokinetic data. J Pharmacokinet Biopharm. 1984;12:545–558. doi: 10.1007/BF01060132. [DOI] [PubMed] [Google Scholar]
  • 6.Sheiner LB, Beal SL. Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. J Pharmacokinet Biopharm. 1985;13:185–201. doi: 10.1007/BF01059398. [DOI] [PubMed] [Google Scholar]
  • 7.Vozeh S, Katz G, Steiner V, Follath F. Population pharmacokinetic parameters in patients treated with oral mexiletine. Eur J Clin Pharmacol. 1982;23:445–451. doi: 10.1007/BF00605996. [DOI] [PubMed] [Google Scholar]
  • 8.Grasela TH, Sheiner LB. Population pharmacokinetics of procainamide from routine clinical data. Clin Pharmacokinet. 1984;9:545–554. doi: 10.2165/00003088-198409060-00004. [DOI] [PubMed] [Google Scholar]
  • 9.Grasela T, Donn SM. Neonatal population pharmacokinetics for phenobarbital derived from routine clinical data. Dev Pharmacol Ther. 1985;8:374–383. doi: 10.1159/000457062. [DOI] [PubMed] [Google Scholar]
  • 10.Grasela TH, Antal EJ, Ereshefsky L, Wells BG, Evans RL, Smith RB. An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug-drug interaction. Clin Pharmacol Ther. 1987;42:433–441. doi: 10.1038/clpt.1987.174. [DOI] [PubMed] [Google Scholar]
  • 11.Wahlby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci. 2002;4:E27–E27. doi: 10.1208/ps040427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Maitre PO, Buhrer M, Thomson D, Stanski DR. A three-step approach combining Bayesian regression and NONMEN population analysis: application to midazolam. J Pharmacokinet Biopharm. 1991;19:377–384. doi: 10.1007/BF01061662. [DOI] [PubMed] [Google Scholar]
  • 13.Mandema J, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992;20:511–528. doi: 10.1007/BF01061469. [DOI] [PubMed] [Google Scholar]
  • 14.Hastie TJ, Tibshirani RJ. Generalized Additive Models. New York: Chapman and Hall; 1990. [Google Scholar]
  • 15.Bruno R, Vivier N, Vergniol JC, DePhillips SL, Montay G, Sheiner LB. A population model for docetaxel (Taxotere®): model building and validation. J Pharmacokinet Biopharm. 1996;24:153–172. doi: 10.1007/BF02353487. [DOI] [PubMed] [Google Scholar]
  • 16.Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993;21:735–750. doi: 10.1007/BF01113502. [DOI] [PubMed] [Google Scholar]
  • 17.Laporte-Simitsidis S, Girard P, Mismetti P, Chabaud S, Decousus H, Boissel JP. Inter-study variability in population pharmacokinetic analysis: when and how to estimate it? J Pharm Sci. 2000;89:155–166. doi: 10.1002/(SICI)1520-6017(200002)89:2<155::AID-JPS3>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  • 18.Wade JR, Beal SL, Sambol NC. Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis. J Pharmacokinet Biopharm. 1994;22:165–176. doi: 10.1007/BF02353542. [DOI] [PubMed] [Google Scholar]
  • 19.Verbeke G, Molenberghs G. Linear Mixed Models in Practice: A SAS-Oriented Approach. New York: Springer Verlag; 1997. [Google Scholar]
  • 20.Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001;28:231–252. doi: 10.1023/A:1011527125570. [DOI] [PubMed] [Google Scholar]
  • 21.Wahlby U, Bouw MR, Jonsson EN, Karlsson MO. Assessment of type I error rates for statistical sub-model in NONMEM. J Pharmacokinet Pharmacodyn. 2002;29:251–269. doi: 10.1023/A:1020254823597. [DOI] [PubMed] [Google Scholar]
  • 22.Stram DO, Lee JW. Variance components testing in the longitudinal mixed effects model. Biometries. 1994;50:1171–1177. doi: 10.2307/2533455. [DOI] [PubMed] [Google Scholar]
  • 23.Pinheiro JC, Bates DM. Mixed-Effect Models in S and S-Plus. New York: Springer Verlag; 2000. [Google Scholar]
  • 24.Aarons L, Balant LP, Mentre F, Morselli PL, Rowland M, Steimer J-L, Vozeh S. Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies. Eur J Clin Pharmacol. 1996;49:251–254. doi: 10.1007/BF00226323. [DOI] [PubMed] [Google Scholar]
  • 25.Kowalski K, Hutmacher MM. Design evaluation for a population pharmacokinetic study using clinical trial simulation: a case study. Stat Med. 2001;20:75–91. doi: 10.1002/1097-0258(20010115)20:1<75::AID-SIM602>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  • 26.Lee PID. Design and power of a population pharmacokinetic study. Pharm Res. 2001;18:75–82. doi: 10.1023/A:1011030827847. [DOI] [PubMed] [Google Scholar]
  • 27.Green D, Duffull SB. Prospective evaluation of a D-optimal designed population pharmacokinetic study. J Pharmacokinet Pharmacodyn. 2003;30:145–161. doi: 10.1023/A:1024467714170. [DOI] [PubMed] [Google Scholar]
  • 28.Duffull SB, Retout S, Mentre F. The use of simulated annealing for finding optimal population designs. Comput Methods Programs Biomed. 2002;69:25–35. doi: 10.1016/S0169-2607(01)00178-X. [DOI] [PubMed] [Google Scholar]
  • 29.Karlsson MO, Jonsson EN, Wiltse CG, Wade JR. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm. 1998;26:207–246. doi: 10.1023/A:1020561807903. [DOI] [PubMed] [Google Scholar]
  • 30.Bonate PL. The effect of collinearity on parameter estimates in nonlinear mixed effect models. Pharm Res. 1999;16:709–717. doi: 10.1023/A:1018828709196. [DOI] [PubMed] [Google Scholar]
  • 31.Hartford A, Davidian M. Consequences of misspecifying assumptions in nonlinear mixed effects models. Comp Stat Data Anal. 2000;34:139–164. doi: 10.1016/S0167-9473(99)00076-6. [DOI] [Google Scholar]
  • 32.Ette EI, Williams PJ, Kim YH, Lane JR, Liu M-J, Capparelli EV. Model appropriateness and pharmacokinetic modeling. J Clin Pharmacol. 2003;43:610–623. [PubMed] [Google Scholar]
  • 33.Bruno R, Baille P, Retout S, Vivier N, Veyrat-Follet C, Sanderlink G-J, Becker R, Antman EM. Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. Br J Clin Pharmacol. 2003;56:407–414. doi: 10.1046/j.1365-2125.2003.01904.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Rajagopalan P, Gastonguay MR. Population pharmacokinetics of ciprofloxacin in pediatric patients. J Clin Pharmacol. 2003;43:698–710. [PubMed] [Google Scholar]
  • 35.Holford NHG. A size standard for pharmacokinetics. Clin Pharmacokinet. 1996;30:329–332. doi: 10.2165/00003088-199630050-00001. [DOI] [PubMed] [Google Scholar]
  • 36.Grasmader K, Verwohlt PL, Kuhn K-U, Dragicevic A, Widdern O, Zobel A, Hiemke C, Rietschel M, Maier W, Jaehde U, Rao ML. Population pharmacokinetic analysis of mirtazapine. Eur J Clin Pharmacol. 2004;60:473–480. doi: 10.1007/s00228-004-0737-0. [DOI] [PubMed] [Google Scholar]
  • 37.Beal SL, Sheiner LB. Methodology of population pharmacokinetics. In: Garrett ER, Hirtz JL, editors. Drug Fate and Metabolism: Methods and Techniques. Vol. 5. New York: Marcel Dekker, Inc; 1985. pp. 135–183. [Google Scholar]
  • 38.Sheiner LB, Ludden TM. Population pharmacokinetics/ pharmacodynamics. Annu Rev Pharmacol Toxicol. 1992;32:185–209. doi: 10.1146/annurev.pa.32.040192.001153. [DOI] [PubMed] [Google Scholar]
  • 39.Tett S, Holford NHG, McLachlan AJ. Population pharmacokinetics and pharmacodynamics: an underutilized resource. Drug Inf J. 1998;32:693–710. [Google Scholar]
  • 40.Davidian M, Giltinan DM. Nonlinear Models for Repeated Measures Data. New York: Chapman and Hall; 1995. [Google Scholar]
  • 41.Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York: Springer-Verlag; 2000. [Google Scholar]
  • 42.Population Pharmacokinetics. Washington, DC: Food and Drug Administration; 1999. [Google Scholar]

Articles from The AAPS Journal are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES